Status:

RECRUITING

Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder

Lead Sponsor:

University Hospitals Cleveland Medical Center

Conditions:

Bipolar Disorder

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to use eye-tracking technology to study attentional biases, reward sensitivity, and cognitive control in adult patients with bipolar disorder with or without anxiety and/o...

Eligibility Criteria

Inclusion

  • Inclusion and Exclusion Criteria for Group 1: bipolar disorder without current anxiety or substance use disorder
  • Inclusion Criteria for Group 1:
  • i. Male or female, age 18 or older
  • ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to Diagnostic and Statistical Manual-5 (DSM-5) criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • iii. Currently in a depressive episode or currently in remission from a mood episode
  • iv. Young Mania Rating Scale total score ≤ 8
  • v. In the opinion of the investigator, capable of understanding and complying with protocol requirements
  • vi. In the opinion of the investigator, has the competency to understand and sign the informed consent
  • vii. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
  • b. Exclusion Criteria for Group 1:
  • i. Significant structural brain lesion (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
  • ii. Progressive neurological disease such as neurodegenerative disease
  • iii. Any current psychiatric disorder (other than a current depressive episode) including anxiety disorders, substance use disorders, antisocial personality disorder and borderline personality disorder as assessed by the MINI and clinician assessment.
  • iv. Currently pregnant or planning to become pregnant
  • v. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription
  • vi. Currently taking any steroids, stimulants, or opioid pain killers.
  • vii. Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine.Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
  • viii. Has had electroconvulsive therapy (ECT) treatment within the last 6 months.
  • Inclusion and Exclusion Criteria for Group 2: Bipolar disorder with a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia)
  • a. Inclusion Criteria for Group 2:
  • i. Male or female, age 18 or older
  • ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • iii. Currently in a depressive episode or currently in remission from a mood episode
  • iv. Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • v. Hamilton Anxiety Rating Scale total score ≥ 18
  • vi. Young Mania Rating Scale total score ≤ 8
  • vii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
  • viii. In the opinion of the investigator, has the competency to understand and sign the informed consent
  • ix. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
  • b. Exclusion Criteria for Group 2:
  • i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
  • ii. Progressive neurological disease such as neurodegenerative disease
  • iii. Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD)
  • iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment.
  • v. Currently pregnant or planning to become pregnant
  • vi. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription
  • vii. Currently taking any steroids, stimulants, or opioid pain killers.
  • viii. Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine
  • ix. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
  • x. Has had ECT treatment within the last 6 months.
  • Inclusion and Exclusion Criteria for Group 3: Bipolar disorder with a current anxiety disorder and a current substance use disorder
  • a. Inclusion Criteria for Group 3:
  • i. Male or female, age 18 or older
  • ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • iii. Meets diagnostic criteria for a substance use disorder within the last 3 months
  • iv. Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • v. Currently in a depressive episode or currently in remission from a mood episode
  • vi. Hamilton Anxiety Rating Scale total score ≥ 18
  • vii. Young Mania Rating Scale total score ≤ 8
  • viii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
  • ix. In the opinion of the investigator, has the competency to understand and sign the informed consent
  • x. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
  • b. Exclusion Criteria for Group 3:
  • i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
  • ii. Progressive neurological disease such as neurodegenerative disease
  • iii. Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD)
  • iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment.
  • v. Intoxicated or in acute withdrawal state.
  • vi. Currently pregnant or planning to become pregnant.
  • vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
  • viii. Has had ECT treatment within the last 6 months.
  • Inclusion and Exclusion Criteria for Group 4: Bipolar disorder without an anxiety disorder but with a current substance use disorder
  • a. Inclusion Criteria for Group 4:
  • i. Male or female, age 18 or older
  • ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • iii. Meets diagnostic criteria for a substance use disorder within the last 3 months
  • iv. Currently in a depressive episode or currently in remission from a mood episode
  • v. Young Mania Rating Scale total score ≤ 8
  • vi. Hamilton Anxiety Rating Scale total score ≤ 12
  • vii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
  • viii. In the opinion of the investigator, has the competency to understand and sign the informed consent
  • ix. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
  • b. Exclusion Criteria for Group 4:
  • i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
  • ii. Progressive neurological disease such as neurodegenerative disease
  • iii. Any co-occurring current anxiety disorder or attention deficit hyperactivity disorder (ADHD)
  • iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment.
  • v. Intoxicated or in an acute withdrawal state
  • vi. Currently pregnant or planning to become pregnant.
  • vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
  • viii. Has had ECT treatment within the last 6 months.
  • Inclusion and exclusion criteria for Group 5: Healthy Volunteers
  • Inclusion criteria for Group 5:
  • i. Male or female, age 18 or older
  • ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
  • iii. In the opinion of the investigator, has the competency to understand and sign the informed consent
  • iv. Physically healthy as determined by research psychiatrist
  • v. Without any current and/or lifetime psychiatric disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • b. Exclusion Criteria for Group 5:
  • i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
  • ii. Progressive neurological disease such as neurodegenerative disease
  • iii. Any psychiatric disorder including any severe personality disorder
  • iv. Currently pregnant or planning to become pregnant
  • v. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription
  • vi. Currently taking any steroids, stimulants, or opioid pain killers.
  • vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.

Exclusion

    Key Trial Info

    Start Date :

    March 27 2019

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    September 1 2026

    Estimated Enrollment :

    100 Patients enrolled

    Trial Details

    Trial ID

    NCT03829787

    Start Date

    March 27 2019

    End Date

    September 1 2026

    Last Update

    October 10 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University Hospitals Cleveland Medical Center - Mood Disorders Program

    Cleveland, Ohio, United States, 44106